PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Tirzepatide: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for Tirzepatide across studied indications.

Back to Tirzepatide overview

Research Summary

Tirzepatide is the most extensively studied dual GIP/GLP-1 agonist, backed by ~973 human studies. The SURPASS program (T2D) and SURMOUNT program (obesity) collectively demonstrate class-leading efficacy, with SURMOUNT-5 confirming superiority over semaglutide. Long-term CV outcomes data expected ~2028.

Evidence by Indication (5 indications)

Indication Tier Trials Summary
Weight loss (obesity) Tier A 7 SURMOUNT trials demonstrated 20-26% body weight reduction; superior to semaglutide in head-to-head
Type 2 diabetes Tier A 9 SURPASS trials showed HbA1c reductions up to 2.46% — strongest glycemic data for any incretin therapy
Heart failure with preserved EF Tier B 1 SUMMIT trial showed improvement in heart failure symptoms in obese patients
NASH/NAFLD Tier B 1 Phase 2b showed significant NASH resolution without worsening fibrosis
Prediabetes prevention Tier B 1 94% risk reduction in progression from prediabetes to type 2 diabetes

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (13 sources)

  1. 1. Tirzepatide for Obesity Treatment and Diabetes Prevention. Study

    (2025), The New England journal of medicine

  2. 2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Study

    (2025), The New England journal of medicine

  3. 3. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. Study

    (2025), The New England journal of medicine

  4. 4. Tirzepatide for overweight and obesity management. Study

    (2025), Expert opinion on pharmacotherapy

  5. 5. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. Meta-Analysis

    (2024), BMJ (Clinical research ed.)

  6. 6. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Clinical Trial

    (2024), JAMA

  7. 7. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. Clinical Trial

    (2024), JAMA

  8. 8. Tirzepatide: A Review in Type 2 Diabetes. Review

    (2024), Drugs

  9. 9. Medications for Obesity: A Review. Review

    (2024), JAMA

  10. 10. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease. Study

    (2024), American heart journal

  11. 11. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Clinical Trial

    (2022), The New England journal of medicine

  12. 12. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Clinical Trial

    (2021), The New England journal of medicine

  13. 13. Tirzepatide versus Placebo in Type 2 Diabetes (SURPASS-1). Clinical Trial

    (2021), The New England journal of medicine